{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=trifluridine%2Ftipiracil&page=3", "query": { "intervention": "trifluridine/tipiracil", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 86, "total_pages": 9, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=trifluridine%2Ftipiracil&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=trifluridine%2Ftipiracil&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-06T19:31:02.675Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01874522", "title": "Study Comparing the Bioavailability of TAS-102 Tablets to an Oral Solution Containing Equivalent Amounts of FTD and TPI", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors (Excluding Breast Cancer)" ], "interventions": [ { "name": "TAS-102 tablets", "type": "DRUG" }, { "name": "TAS-102 oral solution", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Taiho Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2013-07", "completion_date": "2015-11", "has_results": false, "last_update_posted_date": "2024-09-05", "last_synced_at": "2026-10-06T19:31:02.675Z", "location_count": 1, "location_summary": "Scottsdale, Arizona", "locations": [ { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01874522" }, { "nct_id": "NCT03223779", "title": "Study of TAS-102 Plus Radiation Therapy for the Treatment of the Liver in Patients With Hepatic Metastases From Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "TAS-102", "type": "DRUG" }, { "name": "Photon SBRT", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2017-10-13", "completion_date": "2025-10-02", "has_results": false, "last_update_posted_date": "2026-03-12", "last_synced_at": "2026-10-06T19:31:02.675Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03223779" }, { "nct_id": "NCT04511039", "title": "Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Clinical Stage III Gastroesophageal Junction Adenocarcinoma", "Clinical Stage IV Gastroesophageal Junction Adenocarcinoma", "Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma", "Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma A", "Locally Advanced Colorectal Carcinoma", "Locally Advanced Gastroesophageal Junction Adenocarcinoma", "Metastatic Colorectal Adenocarcinoma", "Metastatic Gastroesophageal Junction Adenocarcinoma", "Pathologic Stage III Gastroesophageal Junction Adenocarcinoma", "Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma", "Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma", "Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma", "Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma", "Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma", "Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Stage III Colorectal Cancer AJCC v8", "Stage IIIA Colorectal Cancer AJCC v8", "Stage IIIB Colorectal Cancer AJCC v8", "Stage IIIC Colorectal Cancer AJCC v8", "Stage IV Colorectal Cancer AJCC v8", "Stage IVA Colorectal Cancer AJCC v8", "Stage IVB Colorectal Cancer AJCC v8", "Stage IVC Colorectal Cancer AJCC v8" ], "interventions": [ { "name": "Trifluridine and Tipiracil Hydrochloride", "type": "DRUG" }, { "name": "Talazoparib Tosylate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2021-06-08", "completion_date": "2029-04-01", "has_results": false, "last_update_posted_date": "2026-05-04", "last_synced_at": "2026-10-06T19:31:02.675Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04511039" }, { "nct_id": "NCT04417699", "title": "SHOrt Course Radiation and TASOX (TAS102 Plus Oxaliplatin) Chemotherapy in Operable Rectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rectal Cancer" ], "interventions": [ { "name": "TAS 102", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Providence Health & Services", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2022-07-05", "completion_date": "2024-02-21", "has_results": true, "last_update_posted_date": "2025-12-10", "last_synced_at": "2026-10-06T19:31:02.675Z", "location_count": 4, "location_summary": "Orange, California • New York, New York • Portland, Oregon + 1 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "Portland", "state": "Oregon" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT04417699" }, { "nct_id": "NCT05848739", "title": "A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colon Cancer", "Metastatic Colon Cancer" ], "interventions": [ { "name": "ST316", "type": "DRUG" }, { "name": "FOLFIRI regimen & bevacizumab", "type": "DRUG" }, { "name": "Fruquintinib", "type": "DRUG" }, { "name": "Lonsurf & bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sapience Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 130, "start_date": "2023-06-05", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-10-06T19:31:02.675Z", "location_count": 11, "location_summary": "Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 8 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05848739" }, { "nct_id": "NCT05608044", "title": "A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "Botensilimab", "type": "DRUG" }, { "name": "Balstilimab", "type": "DRUG" }, { "name": "Standard of Care", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Agenus Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 234, "start_date": "2022-11-30", "completion_date": "2029-09", "has_results": false, "last_update_posted_date": "2025-09-04", "last_synced_at": "2026-10-06T19:31:02.675Z", "location_count": 26, "location_summary": "Scottsdale, Arizona • Duarte, California • Los Angeles, California + 18 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05608044" }, { "nct_id": "NCT04920032", "title": "Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colon Adenocarcinoma", "Colorectal Cancer" ], "interventions": [ { "name": "TAS-102", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Standard Treatment", "type": "COMBINATION_PRODUCT" }, { "name": "Signatera MRD ctDNA Assay", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT", "DIAGNOSTIC_TEST" ], "sponsor": "University of California, Irvine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2021-08-26", "completion_date": "2028-01-21", "has_results": false, "last_update_posted_date": "2026-05-11", "last_synced_at": "2026-10-06T19:31:02.675Z", "location_count": 1, "location_summary": "Orange, California", "locations": [ { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04920032" }, { "nct_id": "NCT05083481", "title": "A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "ASP1570", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" }, { "name": "Trifluridine + Tipiracil", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 226, "start_date": "2021-10-19", "completion_date": "2026-05-11", "has_results": false, "last_update_posted_date": "2026-08-14", "last_synced_at": "2026-10-06T19:31:02.675Z", "location_count": 12, "location_summary": "Fullerton, California • Los Angeles, California • Sarasota, Florida + 8 more", "locations": [ { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05083481" }, { "nct_id": "NCT07861360", "title": "Emulation of the SUNLIGHT Trial Using Specialty Oncology Electronic Health Records Databases", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Metastatic Colorectal Cancer (mCRC)" ], "interventions": [ { "name": "Initiation of trifluridine-tipiracil plus bevacizumab", "type": "DRUG" }, { "name": "Initiation of trifluridine-tipiracil alone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 400, "start_date": "2026-09-24", "completion_date": "2026-12-24", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-10-06T19:31:02.675Z", "location_count": 1, "location_summary": "Somerville, Massachusetts", "locations": [ { "city": "Somerville", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07861360" }, { "nct_id": "NCT04879368", "title": "RegoNivo vs Standard of Care Chemotherapy in AGOC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Gastro-Oesophageal Cancer" ], "interventions": [ { "name": "Regorafenib", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Trifluridine/Tipracil", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Australasian Gastro-Intestinal Trials Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 462, "start_date": "2021-05-05", "completion_date": "2025-04-30", "has_results": true, "last_update_posted_date": "2026-06-10", "last_synced_at": "2026-10-06T19:31:02.675Z", "location_count": 6, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Sioux City, Iowa + 3 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sioux City", "state": "Iowa" }, { "city": "Edgewood", "state": "Kentucky" }, { "city": "Rapid City", "state": "South Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04879368" } ] }